George, J, Shafiq, K, Kapadia, M, Kalia, LV, Kalia, SK. High frequency electrical stimulation reduces α-synuclein levels and α-synuclein-mediated autophagy dysfunction. Sci Rep. 2024;14 (1):16091. doi: 10.1038/s41598-024-64131-3. PubMed PMID:38997273 PubMed Central PMC11245498.

Beckers, M, Coburn, B, Kalia, LV, Bloem, BR. A Randomized Controlled Trial of Fecal Microbiota Transplantation for Parkinson's Disease: Getting it right, if not PARFECT. J Parkinsons Dis. 2024; :. doi: 10.3233/JPD-249007. PubMed PMID:38968058 .

Burré, J, Edwards, RH, Halliday, G, Lang, AE, Lashuel, HA, Melki, R et al.. Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis. Mov Disord. 2024; :. doi: 10.1002/mds.29897. PubMed PMID:38946200 .

Kalbe, E, Bloem, BR, Kalia, LV, Nieuwboer, A. Non-Pharmacological Interventions for People with Parkinson's Disease: Are We Entering a New Era?. J Parkinsons Dis. 2024; :. doi: 10.3233/JPD-249006. PubMed PMID:38943399 .

Meng, Y, Kalia, LV, Kalia, SK, Hamani, C, Huang, Y, Hynynen, K et al.. Current Progress in Magnetic Resonance-Guided Focused Ultrasound to Facilitate Drug Delivery across the Blood-Brain Barrier. Pharmaceutics. 2024;16 (6):. doi: 10.3390/pharmaceutics16060719. PubMed PMID:38931843 PubMed Central PMC11206305.

Gros, P, Spee, BTM, Bloem, BR, Kalia, LV. If Art Were a Drug: Implications for Parkinson's Disease. J Parkinsons Dis. 2024; :. doi: 10.3233/JPD-240031. PubMed PMID:38788090 .

Kalia, LV, Bloem, BR. Sharing Advice that We Give to People with Parkinson's Disease. J Parkinsons Dis. 2024;14 (3):361-362. doi: 10.3233/JPD-249003. PubMed PMID:38669485 PubMed Central PMC11091572.

Hui, S, George, J, Kapadia, M, Chau, H, Bariring, Z, Earnshaw, R et al.. Mitophagy Upregulation Occurs Early in the Neurodegenerative Process Mediated by α-Synuclein. Mol Neurobiol. 2024; :. doi: 10.1007/s12035-024-04131-6. PubMed PMID:38581539 .

Davidson, B, Milosevic, L, Kondrataviciute, L, Kalia, LV, Kalia, SK. Neuroscience fundamentals relevant to neuromodulation: Neurobiology of deep brain stimulation in Parkinson's disease. Neurotherapeutics. 2024;21 (3):e00348. doi: 10.1016/j.neurot.2024.e00348. PubMed PMID:38579455 PubMed Central PMC11000190.

Outeiro, TF, Kalia, LV, Bezard, E, Ferrario, J, Lin, CH, Salama, M et al.. Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice. Mov Disord. 2024;39 (6):929-933. doi: 10.1002/mds.29802. PubMed PMID:38576081 .

Schneider, RB, Phillips, O, Kalia, L. Conventionvs. Innovation I: Digital technology will replace clinic-based care in Parkinson disease. Parkinsonism Relat Disord. 2024; :106067. doi: 10.1016/j.parkreldis.2024.106067. PubMed PMID:38443214 .

Lee, EJ, Aguirre-Padilla, DH, Fomenko, A, Pawar, G, Kapadia, M, George, J et al.. Reduction of alpha-synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo. Brain Stimul. 2024;17 (2):166-175. doi: 10.1016/j.brs.2024.02.005. PubMed PMID:38342364 .

Bloem, BR, Kalia, LV. Kathrin Brockmann, Milan Zimmermann, and Dareia Roos, Recipients of The Parkinson Prize 2023. J Parkinsons Dis. 2023;13 (8):1273-1276. doi: 10.3233/JPD-239006. PubMed PMID:38143375 PubMed Central PMC10741366.

Bhidayasiri, R, Kalia, LV, Bloem, BR. Tackling Parkinson's Disease as a Global Challenge. J Parkinsons Dis. 2023;13 (8):1277-1280. doi: 10.3233/JPD-239005. PubMed PMID:38143374 PubMed Central PMC10741319.

Mestre, TA, Kalia, LV. α-synuclein seed amplification in Parkinson's disease. Lancet Neurol. 2023;22 (11):984-985. doi: 10.1016/S1474-4422(23)00374-5. PubMed PMID:37863603 .

Albanese, F, Bloem, BR, Kalia, LV. Addressing the "Replication Crisis" in the Field of Parkinson's Disease. J Parkinsons Dis. 2023;13 (6):849-850. doi: 10.3233/JPD-239002. PubMed PMID:37694309 PubMed Central PMC10578279.

Lang, S, Vetkas, A, Conner, C, Kalia, LV, Lozano, AM, Kalia, SK et al.. Predictors of Future Deep Brain Stimulation Surgery in de novo Parkinson's Disease. Mov Disord Clin Pract. 2023;10 (6):933-942. doi: 10.1002/mdc3.13747. PubMed PMID:37332645 PubMed Central PMC10272891.

Nim, S, O'Hara, DM, Corbi-Verge, C, Perez-Riba, A, Fujisawa, K, Kapadia, M et al.. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Nat Commun. 2023;14 (1):2150. doi: 10.1038/s41467-023-37464-2. PubMed PMID:37076542 PubMed Central PMC10115881.

McFarthing, K, Bloem, BR, Kalia, LV. People with Parkinson's as Partners for the Journal of Parkinson's Disease. J Parkinsons Dis. 2023;13 (2):125-126. doi: 10.3233/JPD-239000. PubMed PMID:36911950 PubMed Central PMC10041413.

Kalia, LV, Nimmo, GAM, Mestre, TA. Genetic Testing in Clinical Movement Disorders: A Case-Based Review. Semin Neurol. 2023;43 (1):147-155. doi: 10.1055/s-0043-1763507. PubMed PMID:36854393 .

Bloem, BR, Kalia, LV. The Journal of Parkinson's Disease Takes the Open Road. J Parkinsons Dis. 2023;13 (1):1-2. doi: 10.3233/JPD-229011. PubMed PMID:36744347 PubMed Central PMC9912718.

Bloem, BR, Kalia, LV. Thomas G. Beach, MD, PhD, FRCPC, Charles H. Adler, MD, PhD, FAAN, and Simon Stott, PhD, recipients of the Parkinson Prize 2022. J Parkinsons Dis. 2022;12 (8):2283-2286. doi: 10.3233/JPD-229010. PubMed PMID:36565068 .

Huang, Y, Meng, Y, Pople, CB, Bethune, A, Jones, RM, Abrahao, A et al.. Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease. Pharmaceutics. 2022;14 (12):. doi: 10.3390/pharmaceutics14122607. PubMed PMID:36559101 PubMed Central PMC9781334.

Fereshtehnejad, SM, Saleh, PA, Oliveira, LM, Patel, N, Bhowmick, S, Saranza, G et al.. Movement disorders in hereditary spastic paraplegia (HSP): a systematic review and individual participant data meta-analysis. Neurol Sci. 2023;44 (3):947-959. doi: 10.1007/s10072-022-06516-8. PubMed PMID:36441344 PubMed Central PMC9925593.

Kalia, LV. First trials test targeting of α-synuclein for Parkinson disease. Nat Rev Neurol. 2022;18 (12):703-704. doi: 10.1038/s41582-022-00726-6. PubMed PMID:36151474 .

Meng, Y, Pople, CB, Huang, Y, Jones, RM, Ottoy, J, Goubran, M et al.. Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study. Mov Disord. 2022;37 (10):2134-2139. doi: 10.1002/mds.29190. PubMed PMID:36089809 .

Ghadery, CM, Kalia, LV, Connolly, BS. Movement disorders of the mouth: a review of the common phenomenologies. J Neurol. 2022;269 (11):5812-5830. doi: 10.1007/s00415-022-11299-1. PubMed PMID:35904592 .

Kalia, LV, Bloem, BR. A New Chapter for the Journal of Parkinson's Disease. J Parkinsons Dis. 2022;12 (5):1365-1367. doi: 10.3233/JPD-229004. PubMed PMID:35811539 .

Sáenz-Farret, M, Lang, AE, Kalia, L, Cunha, I, Sousa, M, Kuhlman, G et al.. Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. Mov Disord Clin Pract. 2022;9 (4):522-529. doi: 10.1002/mdc3.13437. PubMed PMID:35586535 PubMed Central PMC9092757.

Chen, KS, Menezes, K, Rodgers, JB, O'Hara, DM, Tran, N, Fujisawa, K et al.. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol Neurodegener. 2021;16 (1):77. doi: 10.1186/s13024-021-00497-6. PubMed PMID:34772429 PubMed Central PMC8588601.

Oliveira, LM, Rastin, T, Nimmo, GAM, Ross, JP, Dion, PA, Zhang, M et al.. Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurol Genet. 2021;7 (4):e600. doi: 10.1212/NXG.0000000000000600. PubMed PMID:34017912 PubMed Central PMC8130998.

Barbuti, PA, Barker, RA, Brundin, P, Przedborski, S, Papa, SM, Kalia, LV et al.. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Mov Disord. 2021;36 (8):1772-1780. doi: 10.1002/mds.28628. PubMed PMID:33963552 .

O'Hara, DM, Kapadia, M, Ping, S, Kalia, SK, Kalia, LV. Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. J Vis Exp. 2021; (168):. doi: 10.3791/62062. PubMed PMID:33616088 .

Bloem, BR, Trenkwalder, C, Sanchez-Ferro, A, Kalia, LV, Alcalay, R, Chiang, HL et al.. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. J Parkinsons Dis. 2021;11 (1):3-8. doi: 10.3233/JPD-212573. PubMed PMID:33523021 PubMed Central PMC7990445.

Branfield Day, L, Rajendram, P, Kalia, LV, Gold, WL. An Intelligent Diagnosis: SMART Syndrome. Am J Med. 2021;134 (7):863-865. doi: 10.1016/j.amjmed.2020.11.034. PubMed PMID:33444593 .

Saranza, G, Chen, KS, Ganos, C, Kalia, LV, Chen, R, Lang, AE et al.. Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. Can J Neurol Sci. 2021;48 (6):864-868. doi: 10.1017/cjn.2020.280. PubMed PMID:33397526 .

Visanji, NP, Madan, P, Lacoste, AMB, Buleje, I, Han, Y, Spangler, S et al.. Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiol Drug Saf. 2021;30 (2):201-209. doi: 10.1002/pds.5176. PubMed PMID:33219601 .

Mylvaganam, S, Earnshaw, R, Heymann, G, Kalia, SK, Kalia, LV. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Curr Neuropharmacol. 2021;19 (7):1038-1068. doi: 10.2174/1570159X18666201116145507. PubMed PMID:33200713 PubMed Central PMC8686314.

Mukherjee, T, Ramaglia, V, Abdel-Nour, M, Bianchi, AA, Tsalikis, J, Chau, HN et al.. The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. J Biol Chem. 2021;296 :100050. doi: 10.1074/jbc.RA120.014415. PubMed PMID:33168630 PubMed Central PMC7948985.

Kapadia, M, De Snoo, ML, Kalia, LV, Kalia, SK. Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members. Neural Regen Res. 2021;16 (4):684-685. doi: 10.4103/1673-5374.295330. PubMed PMID:33063725 PubMed Central PMC8067924.

Friesen, EL, Zhang, YT, Earnshaw, R, De Snoo, ML, O'Hara, DM, Agapova, V et al.. BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Front Cell Dev Biol. 2020;8 :716. doi: 10.3389/fcell.2020.00716. PubMed PMID:32850835 PubMed Central PMC7417480.

Meng, Y, Pople, CB, Kalia, SK, Kalia, LV, Davidson, B, Bigioni, L et al.. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease. J Neurosurg. 2020;135 (1):273-278. doi: 10.3171/2020.5.JNS20692. PubMed PMID:32764177 .

O'Hara, DM, Pawar, G, Kalia, SK, Kalia, LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?. Front Neurosci. 2020;14 :577. doi: 10.3389/fnins.2020.00577. PubMed PMID:32625052 PubMed Central PMC7311858.

Fomenko, A, Lee, DJ, McKinnon, C, Lee, EJ, de Snoo, ML, Gondard, E et al.. Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus. Front Neurosci. 2020;14 :463. doi: 10.3389/fnins.2020.00463. PubMed PMID:32477058 PubMed Central PMC7235415.

Maclagan, LC, Visanji, NP, Cheng, Y, Tadrous, M, Lacoste, AMB, Kalia, LV et al.. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29 (8):864-872. doi: 10.1002/pds.5015. PubMed PMID:32410265 .

O'Hara, DM, Kalia, SK, Kalia, LV. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. Crit Rev Clin Lab Sci. 2020;57 (5):291-307. doi: 10.1080/10408363.2019.1711359. PubMed PMID:32116096 .

Espay, AJ, Kalia, LV, Gan-Or, Z, Williams-Gray, CH, Bedard, PL, Rowe, SM et al.. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. Neurology. 2020;94 (11):481-494. doi: 10.1212/WNL.0000000000009107. PubMed PMID:32102975 PubMed Central PMC7220234.

McKinnon, C, De Snoo, ML, Gondard, E, Neudorfer, C, Chau, H, Ngana, SG et al.. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathol Commun. 2020;8 (1):17. doi: 10.1186/s40478-020-0894-0. PubMed PMID:32059750 PubMed Central PMC7023783.

De Snoo, ML, Friesen, EL, Zhang, YT, Earnshaw, R, Dorval, G, Kapadia, M et al.. Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. Cell Death Dis. 2019;10 (12):907. doi: 10.1038/s41419-019-2132-x. PubMed PMID:31787745 PubMed Central PMC6885512.

Kalia, LV. Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease". Parkinsonism Relat Disord. 2020;74 :78-79. doi: 10.1016/j.parkreldis.2019.11.005. PubMed PMID:31727562 .

Kalia, LV, Jellinger, KA. Multiple system atrophy and myoclonus: A morphologic marker in the spinal cord?. Neurology. 2019;93 (7):287-288. doi: 10.1212/WNL.0000000000007941. PubMed PMID:31405931 .

Rajalingam, R, Breen, DP, Chen, R, Fox, S, Kalia, LV, Munhoz, RP et al.. The clinical significance of lower limb tremors. Parkinsonism Relat Disord. 2019;65 :165-171. doi: 10.1016/j.parkreldis.2019.06.007. PubMed PMID:31201091 .

McKinnon, C, Gros, P, Lee, DJ, Hamani, C, Lozano, AM, Kalia, LV et al.. Deep brain stimulation: potential for neuroprotection. Ann Clin Transl Neurol. 2019;6 (1):174-185. doi: 10.1002/acn3.682. PubMed PMID:30656196 PubMed Central PMC6331208.

Kalia, LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism Relat Disord. 2019;59 :21-25. doi: 10.1016/j.parkreldis.2018.11.016. PubMed PMID:30466800 .

Picillo, M, Lizarraga, KJ, Friesen, EL, Chau, H, Zhang, M, Sato, C et al.. Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. Mov Disord. 2018;33 (12):1950-1955. doi: 10.1002/mds.27506. PubMed PMID:30423204 .

Coakeley, S, Ang, LC, Jansen, GH, Cho, SS, Lang, AE, Houle, S et al.. [18 F]AV-1451 binding and postmortem pathology of CBD. Mov Disord. 2018;33 (8):1360-1361. doi: 10.1002/mds.27356. PubMed PMID:30136331 .

Ruskey, JA, Zhou, S, Santiago, R, Franche, LA, Alam, A, Roncière, L et al.. The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. Clin Genet. 2018;94 (3-4):339-345. doi: 10.1111/cge.13405. PubMed PMID:29920646 .

O'Hara, DM, Kalia, SK, Kalia, LV. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease. Br J Pharmacol. 2018;175 (15):3080-3089. doi: 10.1111/bph.14345. PubMed PMID:29722028 PubMed Central PMC6031880.

Meng, Y, Voisin, MR, Suppiah, S, Kalia, SK, Kalia, LV, Hamani, C et al.. Is there a role for MR-guided focused ultrasound in Parkinson's disease?. Mov Disord. 2018;33 (4):575-579. doi: 10.1002/mds.27308. PubMed PMID:29476631 .

Baskin, B, Kalia, LV, Banwell, BL, Ray, PN, Yoon, G. Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism. Mov Disord. 2017;32 (12):1792-1794. doi: 10.1002/mds.27188. PubMed PMID:29082553 .

Friesen, EL, De Snoo, ML, Rajendran, L, Kalia, LV, Kalia, SK. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. Parkinsons Dis. 2017;2017 :5015307. doi: 10.1155/2017/5015307. PubMed PMID:28913005 PubMed Central PMC5585656.

Park, S, Bin, NR, Yu, B, Wong, R, Sitarska, E, Sugita, K et al.. UNC-18 and Tomosyn Antagonistically Control Synaptic Vesicle Priming Downstream of UNC-13 in Caenorhabditis elegans. J Neurosci. 2017;37 (36):8797-8815. doi: 10.1523/JNEUROSCI.0338-17.2017. PubMed PMID:28821673 PubMed Central PMC5588468.

Kalia, LV. Biomarkers for cognitive dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2018;46 Suppl 1 :S19-S23. doi: 10.1016/j.parkreldis.2017.07.023. PubMed PMID:28781202 .

Koprich, JB, Kalia, LV, Brotchie, JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017;18 (9):515-529. doi: 10.1038/nrn.2017.75. PubMed PMID:28747776 .

Rosborough, K, Patel, N, Kalia, LV. α-Synuclein and Parkinsonism: Updates and Future Perspectives. Curr Neurol Neurosci Rep. 2017;17 (4):31. doi: 10.1007/s11910-017-0737-y. PubMed PMID:28324300 .

Breen, DP, Kalia, LV. Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. Mov Disord. 2017;32 (1):106. doi: 10.1002/mds.26884. PubMed PMID:27896833 .

Visanji, NP, Brotchie, JM, Kalia, LV, Koprich, JB, Tandon, A, Watts, JC et al.. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 2016;39 (11):750-762. doi: 10.1016/j.tins.2016.09.003. PubMed PMID:27776749 .

Rowland, NC, Kalia, SK, Kalia, LV, Larson, PS, Lim, DA, Bankiewicz, KS et al.. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev. 2016;3 :15051. doi: 10.1038/mtm.2015.51. PubMed PMID:26817024 PubMed Central PMC4714520.

Kalia, LV, Lang, AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol. 2016;12 (2):65-6. doi: 10.1038/nrneurol.2015.249. PubMed PMID:26782330 .

Kalia, LV, Kalia, SK, Lang, AE. Disease-modifying strategies for Parkinson's disease. Mov Disord. 2015;30 (11):1442-50. doi: 10.1002/mds.26354. PubMed PMID:26208210 .

Kalia, LV, Kalia, SK. α-Synuclein and Lewy pathology in Parkinson's disease. Curr Opin Neurol. 2015;28 (4):375-81. doi: 10.1097/WCO.0000000000000215. PubMed PMID:26110807 .

Kalia, LV, Lang, AE. Parkinson's disease. Lancet. 2015;386 (9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. PubMed PMID:25904081 .

Shah, BB, Chen, R, Zurowski, M, Kalia, LV, Gunraj, C, Lang, AE et al.. Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. Parkinsonism Relat Disord. 2015;21 (4):407-12. doi: 10.1016/j.parkreldis.2015.01.013. PubMed PMID:25737204 .

Kalia, LV, Lang, AE, Hazrati, LN, Fujioka, S, Wszolek, ZK, Dickson, DW et al.. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72 (1):100-5. doi: 10.1001/jamaneurol.2014.2704. PubMed PMID:25401511 PubMed Central PMC4399368.

Kalia, LV, Rockman-Greenberg, C, Borys, A, Lang, AE. Tremor in Spinocerebellar Ataxia Type 12. Mov Disord Clin Pract. 2014;1 (1):76-78. doi: 10.1002/mdc3.12015. PubMed PMID:30363887 PubMed Central PMC6183183.

Beilina, A, Rudenko, IN, Kaganovich, A, Civiero, L, Chau, H, Kalia, SK et al.. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A. 2014;111 (7):2626-31. doi: 10.1073/pnas.1318306111. PubMed PMID:24510904 PubMed Central PMC3932908.

Dimant, H, Kalia, SK, Kalia, LV, Zhu, LN, Kibuuka, L, Ebrahimi-Fakhari, D et al.. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun. 2013;1 :6. doi: 10.1186/2051-5960-1-6. PubMed PMID:24252244 PubMed Central PMC3776213.

Kalia, LV, Lang, AE, Aviv, RI, Masellis, M. Author response. Neurology. 2013;81 (13):1181. . PubMed PMID:24191352 .

AlDakheel, A, Kalia, LV, Lang, AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11 (1):6-23. doi: 10.1007/s13311-013-0218-1. PubMed PMID:24085420 PubMed Central PMC3899477.

Civardi, C, Collini, A, Kalia, LV, Lang, AE, Aviv, RI, Masellis, M et al.. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. Neurology. 2013;81 (13):1181. doi: 10.1212/WNL.0b013e3182a7a945. PubMed PMID:24062343 .

Kalia, LV, Kalia, SK, McLean, PJ, Lozano, AM, Lang, AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73 (2):155-69. doi: 10.1002/ana.23746. PubMed PMID:23225525 PubMed Central PMC3608838.

Kalia, LV, Brotchie, JM, Fox, SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord. 2013;28 (2):131-44. doi: 10.1002/mds.25273. PubMed PMID:23225267 .

Kalia, LV, Mozessohn, L, Aviv, RI, da Costa, L, Lang, AE, Shadowitz, S et al.. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. Neurology. 2012;78 (11):838-9. doi: 10.1212/WNL.0b013e318249f733. PubMed PMID:22411959 PubMed Central PMC3304947.

Pitcher, GM, Kalia, LV, Ng, D, Goodfellow, NM, Yee, KT, Lambe, EK et al.. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med. 2011;17 (4):470-8. doi: 10.1038/nm.2315. PubMed PMID:21441918 PubMed Central PMC3264662.

Kalia, LV, Kalia, SK, Chau, H, Lozano, AM, Hyman, BT, McLean, PJ et al.. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One. 2011;6 (2):e14695. doi: 10.1371/journal.pone.0014695. PubMed PMID:21358815 PubMed Central PMC3040167.

Kalia, SK, Kalia, LV, McLean, PJ. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets. 2010;9 (6):741-53. doi: 10.2174/187152710793237386. PubMed PMID:20942788 PubMed Central PMC3364514.

Kalia, LV, Lee, L, Kalia, SK, Pirouzmand, F, Rapoport, MJ, Aviv, RI et al.. Thoracic myelopathy from coincident fluorosis and epidural lipomatosis. Can J Neurol Sci. 2010;37 (2):276-8. doi: 10.1017/s0317167100010076. PubMed PMID:20437944 .

Ng, D, Pitcher, GM, Szilard, RK, Sertié, A, Kanisek, M, Clapcote, SJ et al.. Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. PLoS Biol. 2009;7 (2):e41. doi: 10.1371/journal.pbio.1000041. PubMed PMID:19243221 PubMed Central PMC2652390.

Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7 (8):742-55. doi: 10.1016/S1474-4422(08)70165-0. PubMed PMID:18635022 PubMed Central PMC3589564.

Kalia, LV, Pitcher, GM, Pelkey, KA, Salter, MW. PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. EMBO J. 2006;25 (20):4971-82. doi: 10.1038/sj.emboj.7601342. PubMed PMID:16990796 PubMed Central PMC1618112.

Kalia, LV, O'Connor, PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. 2005;11 (3):322-7. doi: 10.1191/1352458505ms1168oa. PubMed PMID:15957515 .

Kalia, LV, Gingrich, JR, Salter, MW. Src in synaptic transmission and plasticity. Oncogene. 2004;23 (48):8007-16. doi: 10.1038/sj.onc.1208158. PubMed PMID:15489918 .

Salter, MW, Kalia, LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5 (4):317-28. doi: 10.1038/nrn1368. PubMed PMID:15034556 .

Kalia, LV, Salter, MW. Interactions between Src family protein tyrosine kinases and PSD-95. Neuropharmacology. 2003;45 (6):720-8. doi: 10.1016/s0028-3908(03)00313-7. PubMed PMID:14529711 .

Fam, SR, Gallagher, CJ, Kalia, LV, Salter, MW. Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes. J Neurosci. 2003;23 (11):4437-44. doi: 10.1523/JNEUROSCI.23-11-04437.2003. PubMed PMID:12805284 PubMed Central PMC6740798.

Kalia, LV. Barriers to women clinician-scientists: a trainee's perspective. Clin Invest Med. 2003;26 (1):15-6. . PubMed PMID:12659464 .

Nong, Y, Huang, YQ, Ju, W, Kalia, LV, Ahmadian, G, Wang, YT et al.. Glycine binding primes NMDA receptor internalization. Nature. 2003;422 (6929):302-7. doi: 10.1038/nature01497. PubMed PMID:12646920 .

Pelkey, KA, Askalan, R, Paul, S, Kalia, LV, Nguyen, TH, Pitcher, GM et al.. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron. 2002;34 (1):127-38. doi: 10.1016/s0896-6273(02)00633-5. PubMed PMID:11931747 .

Regan, D, Hajdur, LV, Hong, XH. Two-dimensional aspect ratio discrimination for shape defined by orientation texture. Vision Res. 1996;36 (22):3695-702. doi: 10.1016/0042-6989(96)00083-1. PubMed PMID:8976999 .

Search PubMed